Theacrine for Health & Longevity
Evidence Review created on 09/26/2026 using AI4L + evidence-mcp / Opus 5.5
Also known as: TeaCrine, 1,3,7,9-tetramethyluric acid, tetramethyluric acid
Motivation
Theacrine (TeaCrine) is a natural compound closely related to caffeine. It occurs in the leaves of kucha, a wild tea plant from southern China, and in a few coffee and cocoa relatives, and it is now sold as a dietary supplement. Like caffeine, it appears to work by blocking the brain’s built-up signal of tiredness.
Its appeal is the promise of steady energy and focus with fewer of caffeine’s drawbacks, such as jitteriness, disturbed sleep, and effects that fade with daily use. It is popular in sports and focus products and has more recently been added to healthy-aging formulas on the strength of animal and cell studies. Most human studies are small, short, and conducted in young adults, and many were funded by the ingredient’s marketer.
This review examines what the evidence shows about theacrine’s effects on energy and mental performance, its safety with regular use, and the basis for its promotion as a healthy-aging aid, with attention to what these findings mean for health-focused adults weighing it against or alongside caffeine.
Benefits - Risks - Protocol - Conclusion
Recommended Reading
This section lists accessible expert commentary, reviews, and key primary studies that give an overview of theacrine.
-
Theacrine as a Potential Caffeine Alternative for Enhanced Ergogenic and Cognitive Performance in Athletes: A Call to Action and Brief Review - Harris & Machek, 2021
A brief narrative review of ergogenic (performance-enhancing) potential, comparing theacrine, a caffeine-like purine alkaloid (plant compound family), with caffeine, including adenosine blocking (adenosine builds sleep pressure in the brain).
-
Theacrine From Camellia kucha and Its Health Beneficial Effects - Sheng et al., 2020
A narrative review of mostly animal and cell research on theacrine’s antioxidant, anti-inflammatory, sleep, cognitive, and fat-metabolism effects, including a discussion of inconsistent findings.
-
Dose response effects of theacrine on cognitive performance and subsequent sleep - Gardiner et al., 2024
An independently funded trial of 100 mg and 400 mg taken 4, 8, or 12 hours before bed, directly testing whether theacrine’s long action costs sleep quality.
-
Safety of TeaCrine®, a non-habituating, naturally-occurring purine alkaloid over eight weeks of continuous use - Taylor et al., 2016
The longest human safety trial: eight weeks of 200–300 mg daily, tracking blood pressure, blood counts, liver and kidney markers, and tolerance; funded by Compound Solutions, which markets TeaCrine.
No directly relevant content was found from Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine, or Lifespan.io; web and on-site searches of each returned no material on theacrine. Rhonda Patrick’s only related content is a brief, members-only Q&A answer on NAD3, a multi-ingredient product, which does not discuss theacrine in depth.
Only four items are listed because few accessible sources discuss theacrine in substantial depth; the list is not padded with marginally relevant content.
Grokipedia
A machine-generated overview of theacrine’s chemistry, plant sources, formation from caffeine in plants, human and animal findings, and safety data; its statements on human benefits are more confident than the trials support.
Examine
Theacrine benefits, dosage, and side effects
Examine judges the research too sparse for conclusions, noting caffeine-like signaling, possibly less tolerance, and rodent data suggesting sedation at low doses and stimulation at higher doses.
ConsumerLab
No ConsumerLab article on theacrine exists; a direct search of consumerlab.com returned no results for theacrine or TeaCrine.
Systematic Reviews
No systematic reviews or meta-analyses for Theacrine were found on PubMed as of September 26, 2026.
Neither the claimed benefits (energy, cognition, exercise performance) nor the principal risks (blood pressure, sleep, liver safety) are therefore represented by a systematic review; the closest syntheses are the narrative reviews under Recommended Reading.
Mechanism of Action
Theacrine (1,3,7,9-tetramethyluric acid) is a purine alkaloid that plants make from caffeine by adding one oxygen atom and one methyl group (Zhang et al., 2020).
- Adenosine blockade: In rats, theacrine reversed the sluggishness caused by drugs that activate adenosine A1 and A2A receptors (the two main brain docking sites through which adenosine promotes sleepiness), indicating it blocks them as caffeine does (Feduccia et al., 2012).
- Dopamine involvement: Its activating effect was reduced by blocking dopamine D1 and D2 receptors (receptors for the brain’s motivation and movement messenger), and repeated dosing produced no tolerance in rats.
- Competing sedative signal: At low oral doses in mice, theacrine instead lengthened drug-induced sleep and raised brain adenosine (Qiao et al., 2017), so its net effect may depend on dose.
- Mitochondrial signaling: In rodent and cell studies, it activated SIRT3 (a sirtuin, one of a family of enzymes that regulate cellular stress responses, working inside mitochondria, the cell’s power plants), proposed to explain liver and nerve-cell protection (Wang et al., 2018).
- Human pharmacology: In eight adults, the half-life (time for blood levels to fall by half) was roughly 16–29 hours, far longer than caffeine’s (He et al., 2017). Caffeine raised theacrine blood levels without changing its half-life, and theacrine did not alter caffeine clearance, suggesting little effect on CYP1A2 (the liver enzyme that breaks down caffeine). Receptor selectivity, tissue distribution beyond the brain, and human metabolic pathways remain uncharacterized.
Historical Context & Evolution
- Plant-chemistry origins: Theacrine was first studied as a plant metabolite. Experiments in the 1960s–1970s found that it caused chromosome breaks in plant root-tip cells (Kihlman, 1977); no published mammalian genetic-damage study was found to confirm or refute this.
- Kucha tea: Kucha, a bitter wild tea from southern China, has long been drunk locally; in 2002 researchers showed that its leaves make theacrine from caffeine (Zheng et al., 2002).
- Animal pharmacology (2007–2013): Chinese and US laboratories reported sedative, anti-inflammatory, pain-relieving, liver-protective, and movement-stimulating effects in rodents (Wang et al., 2010; Feduccia et al., 2012).
- Supplement era (mid-2010s onward): A synthetic, nature-identical form was branded TeaCrine by Compound Solutions and tested in sponsor-funded human trials reporting more energy and no tolerance (Ziegenfuss et al., 2017; Taylor et al., 2016).
- Independent testing (2022 onward): University groups in Brazil, Serbia, Australia, and the US found no performance benefit from theacrine alone, possible blood-pressure and side-effect signals at high doses, and a modest next-morning attention effect (Vieira-Cavalcante et al., 2025; Jovanov et al., 2025; Gardiner et al., 2024; Stoke et al., 2026). The picture has shifted from “caffeine without the downsides” toward “a weaker, longer-acting caffeine relative”, although higher-dose, longer, and older-adult trials could still move it either way.
- Longevity framing: Rodent SIRT3 findings led to theacrine-based healthy-aging products, which have not been tested against aging outcomes in people.
Expected Benefits
High 🟩 🟩 🟩
No benefit reaches High: the human trials are small, mostly single-dose studies in young adults, and none measures a clinical health outcome or consistently replicates a functional benefit of theacrine alone.
Medium 🟩 🟩
Sharper Attention and Reaction Time When Paired With Lower-Dose Caffeine
In randomized, placebo-controlled trials in tactical trainees and soccer players, 125–150 mg theacrine plus 150 mg caffeine improved reaction time (and, in trainees, working-memory accuracy) as much as, or slightly more than, 275–300 mg caffeine alone (Lints et al., 2025; Bello et al., 2019). Theacrine’s own contribution is not isolated, and these trials were funded by, or used products from, Compound Solutions, which markets TeaCrine. For caffeine-sensitive adults, the relevant signal is similar alertness from half the caffeine.
Magnitude: In tactical trainees, the combination sped light-board reaction time by 3.0% and raised working-memory accuracy by 7.3% versus placebo, whereas caffeine alone did not significantly improve that accuracy (Lints et al., 2025).
Low 🟩
Subjective Energy and Reduced Fatigue ⚠️ Conflicted
A 200 mg dose raised energy and concentration and lowered fatigue versus placebo in a 15-adult sponsor-funded trial (Ziegenfuss et al., 2017). Trials at 300 mg (Cesareo et al., 2019) or 3–9 mg/kg (Stoke et al., 2026) found no energy gain. The net reading is a small, inconsistent subjective effect.
Magnitude: At 300 mg, energy ratings did not differ from placebo, while 300 mg caffeine raised them 9.8% above theacrine (Cesareo et al., 2019).
Objective Attention and Thinking Performance ⚠️ Conflicted
In an independent trial, 400 mg taken four or eight hours before bed reduced next-morning attention lapses; 100 mg had no effect (Gardiner et al., 2024). A 3–9 mg/kg trial found no cognitive change with theacrine alone (Stoke et al., 2026). The net reading is a possible, unconfirmed high-dose effect.
Magnitude: 400 mg reduced lapses on a sustained-attention reaction test by about 1.1–1.2 per session versus placebo, a small effect, with no change in average reaction time (Gardiner et al., 2024).
Endurance and Strength Performance ⚠️ Conflicted
Soccer players’ time to exhaustion trended longer with theacrine (Bello et al., 2019). Cycling (Vieira-Cavalcante et al., 2025), lifting (Cesareo et al., 2019), canoe (Jovanov et al., 2025), and flag-football (Cerqueira et al., 2022) trials found no gain from theacrine alone. The net reading is no reliable exercise benefit.
Magnitude: Time to exhaustion was 27–38% longer than placebo in the soccer trial, short of statistical significance (Bello et al., 2019), while 4 km cycling time was unchanged at 3 or 6 mg/kg (Vieira-Cavalcante et al., 2025).
Sustained Response Without Tolerance
In a placebo-controlled trial, 40 young adults taking 200 or 300 mg daily for eight weeks kept stable pre-dose energy, focus, and mood ratings, which the sponsor-funded authors read as absence of tolerance (Taylor et al., 2016). Post-dose effects were not compared over time, so preserved benefit is inferred.
Magnitude: Pre-dose energy, focus, anxiety, and mood scores did not change across eight weeks at 200–300 mg/day; the study reports no numeric estimate of tolerance (Taylor et al., 2016).
Speculative 🟨
Liver Fat and Lipid Metabolism
In high-fat-fed mice, theacrine reduced fatty liver and liver inflammation by activating SIRT3 and fat burning (Wang et al., 2018). No human liver data exist.
Mood and Stress Resilience
In chronically stressed mice, theacrine reduced depression-like behavior and supported new nerve-cell growth in the hippocampus (the brain’s memory center) (Ouyang et al., 2021). Evidence is animal-only.
Brain Cell Protection
In rat, mouse, and zebrafish models of Parkinson’s disease, theacrine preserved dopamine-producing neurons via SIRT3 (Duan et al., 2020). No human neurological data exist.
Anti-Inflammatory and Pain-Relieving Effects
Oral theacrine reduced swelling and pain responses in rodents, whereas caffeine at matching doses did not (Wang et al., 2010). Human data are absent.
Cellular Aging Pathways
NAD3, a Compound Solutions theacrine blend, raised NAD+ (an energy coenzyme) and sirtuin activity in mouse muscle cells (Mumford et al., 2020). Evidence is cell-based; human data cover only stem-cell counts (Hellenbrand et al., 2024).
Sleep Promotion at Low Doses
In mice, a low oral dose lengthened drug-induced sleep through adenosine signaling (Qiao et al., 2017). No human trial has tested low-dose theacrine for sleep.
Stroke and Kidney Injury Protection
Theacrine reduced brain damage after induced stroke in rats (Zhang et al., 2026) and eased infection-triggered acute kidney injury in mice (Yang et al., 2022). Evidence is animal- and cell-based only.
Anti-Tumor Activity
Theacrine slowed chemically induced breast tumors in rats (Jhuo et al., 2021). Evidence is limited to animal and cell-culture studies.
Benefit-Modifying Factors
- Genetic variation in caffeine handling: CYP1A2*1F status (a fast-metabolizer variant of the caffeine-clearing enzyme gene) did not change responses to a blend of caffeine, theacrine, and methylliberine (a related caffeine-like compound) (Tartar et al., 2021); ADORA2A variants (adenosine A2A receptor gene) remain untested.
- Baseline caffeine habits: In habitual caffeine users, theacrine produced no energy or cognitive gain even at 9 mg/kg (Stoke et al., 2026); most positive trials required caffeine abstinence beforehand.
- Baseline alertness: Benefits appeared as fewer attention lapses, which are more common when baseline sleepiness is high; people with normal baseline vigilance scores may notice little change.
- Sex: Most trials enrolled mainly young men and none reported sex-specific analyses, so whether women respond differently is unknown.
- Pre-existing conditions: No trial enrolled people with fatigue disorders, depression, fatty liver, or neurodegenerative disease, the conditions where animal data suggest benefit.
- Age: Nearly all trials enrolled adults in their twenties; only a small seven-day study of a theacrine blend included ages 40–70 (Hellenbrand et al., 2024). Age-related changes in adenosine receptors and sleep could alter benefit in older adults.
Potential Risks & Side Effects
High 🟥 🟥 🟥
No risk reaches High: adverse events come from a single small trial, and no study reports clinical events such as heart-rhythm problems, hospitalization, or liver injury in people.
Medium 🟥 🟥
Stimulant-Type Side Effects at Higher Doses
In an independent trial of 19 trained cyclists, 3 or 6 mg/kg (about 225–450 mg for a 75 kg adult) produced digestive discomfort, a sensation of racing heart, dizziness, headache, head pressure, hand tremor, and low motivation (Vieira-Cavalcante et al., 2025). By contrast, 200–300 mg daily for eight weeks produced no abnormal safety markers (Taylor et al., 2016). The effects appear dose-related and resemble caffeine’s; no lasting effects were reported.
Magnitude: Side effects were reported at both 3 and 6 mg/kg, but the literature reports no incidence figure; no adverse events were reported at 200–300 mg/day for eight weeks (Taylor et al., 2016).
Low 🟥
Blood Pressure Elevation ⚠️ Conflicted
A 6 mg/kg dose raised resting systolic and diastolic pressure in cyclists (Vieira-Cavalcante et al., 2025), whereas 3–9 mg/kg (Stoke et al., 2026) and 200–300 mg daily for eight weeks (Taylor et al., 2016) did not. The net reading is a possible rise at high single doses.
Magnitude: At 6 mg/kg, resting systolic and diastolic pressure rose significantly versus placebo, but the literature reports no size of the rise; no change occurred at 3–9 mg/kg in another trial (Stoke et al., 2026).
Poorer Sleep After High Doses
In an independent trial, 400 mg taken eight hours before bed modestly worsened objective sleep versus 100 mg; objective differences versus placebo were not significant (Gardiner et al., 2024). Even 12 hours before bed, 400 mg lengthened perceived time to fall asleep versus placebo.
Magnitude: Taken eight hours before bed, 400 mg lowered sleep efficiency by 7.5% and added about 30 minutes of night-time wakefulness compared with 100 mg; versus placebo, sleep efficiency fell 5.5% (not significant) (Gardiner et al., 2024).
Speculative 🟨
Liver Injury at Very High Doses
In a 90-day rat study, 300–375 mg/kg daily caused fatal liver-cell death in three animals, while 180 mg/kg daily produced no adverse findings (Clewell et al., 2016). Evidence is animal-only.
Male Reproductive Toxicity
The same rat study found lighter testes and reduced sperm production at 300 mg/kg daily or more (Clewell et al., 2016). These doses far exceed human intake, and human data are absent.
Chromosome Damage
Early plant-cell experiments classed theacrine as chromosome-damaging (Kihlman, 1977). No mammalian genetic-damage studies were found, so relevance to humans is unknown.
Stress-Hormone Rise
Doses of 3–9 mg/kg raised salivary cortisol (the main stress hormone) versus placebo in habitual caffeine users (Stoke et al., 2026). This is a biomarker change without outcome data.
Risk-Modifying Factors
- Caffeine-sensitivity genes: ADORA2A and CYP1A2 variants linked to caffeine-induced anxiety or poor sleep could plausibly raise sensitivity to theacrine; this has not been studied.
- Baseline blood pressure: Readings at or above 130/80 mmHg leave less margin for the rise seen at high doses; trials excluded people with high blood pressure.
- Sex and hormonal status: No sex differences in side effects have been reported. Pregnancy and oral contraceptives slow caffeine clearance, which may heighten combined caffeine–theacrine effects.
- Pre-existing conditions: Anxiety or panic disorder, insomnia, heart-rhythm disorders, and liver disease were excluded or untested; stimulant effects and rat liver findings make these groups the most uncertain.
- Age: Older adults generally have lighter sleep, higher blood pressure, and slower drug clearance; with a half-life near a day, sleep effects may be greater, and no trial has tested adults over 70.
Key Interactions & Contraindications
- Caffeine (supplements, coffee, tea, energy drinks): Monitor. Caffeine raised theacrine peak levels and total exposure (He et al., 2017), potentially amplifying stimulant effects. Mitigation: combined use at the tested 50–150 mg theacrine with no more than 150 mg caffeine.
- Prescription stimulants for attention-deficit/hyperactivity disorder (amphetamine, methylphenidate, modafinil): Caution. Additive stimulation may raise heart rate, blood pressure, anxiety, and insomnia. Mitigation: prescriber review, a 50 mg start, and home blood-pressure checks.
- Monoamine oxidase inhibitors (older antidepressants that block breakdown of stimulating brain chemicals; phenelzine, tranylcypromine, selegiline): Caution (theoretical). Dopamine involvement suggests possible additive blood-pressure or agitation effects; no data exist. Mitigation: avoidance during treatment.
- Blood-pressure medications (amlodipine, lisinopril, losartan): Monitor. High theacrine doses may partly counter blood-pressure control. Mitigation: home readings during the first two weeks.
- Sedatives and sleep medications (zolpidem; benzodiazepines, calming sedatives such as alprazolam): Monitor. Adenosine blockade may blunt sedation, while low doses enhanced sleep in mice, so direction is uncertain. Mitigation: morning-only dosing.
- Adenosine or regadenoson for cardiac stress testing: Caution. Like caffeine, theacrine may block these test drugs and cause a falsely normal result. Mitigation: stopping theacrine at least 5 days beforehand, given its long half-life.
- Over-the-counter decongestants and caffeine-containing pain relievers (pseudoephedrine, phenylephrine, Excedrin): Monitor. Additive stimulant and blood-pressure effects. Mitigation: avoiding same-day high-dose theacrine.
- Over-the-counter sleep aids (diphenhydramine, doxylamine): Monitor. Opposing effects may reduce sleep-aid effectiveness. Mitigation: morning dosing of theacrine.
- Stimulant supplements (methylliberine, synephrine, yohimbine, guarana, yerba mate, green tea extract): Caution. Additive heart-rate, blood-pressure, and anxiety effects; several are hidden caffeine sources. Mitigation: tallying total daily stimulant intake.
- L-theanine: Monitor. Often paired because it may soften stimulant jitteriness and blunt theacrine’s felt effect; no trial has tested the pair’s safety or benefit. Mitigation: introducing one product at a time.
- Alcohol: Monitor. Stimulants can mask alcohol’s sedating effect and encourage heavier drinking; no theacrine-specific data exist. Mitigation: avoiding same-evening combination.
Populations who should avoid Theacrine:
- Pregnant or breastfeeding women (no safety data)
- Children and adolescents under 18 years
- Uncontrolled high blood pressure (resting ≥140/90 mmHg)
- Heart-rhythm disorders, or heart attack or stroke within the past 90 days
- Active liver disease (liver enzymes above 3 times the upper limit of normal) or Child-Pugh Class B–C cirrhosis (moderate-to-severe liver scarring)
- Panic disorder, severe anxiety disorder, or chronic insomnia
- Anyone scheduled for an adenosine or regadenoson cardiac stress test within 5 days
Risk Mitigation Strategies
- Low starting dose: Starting at 50–100 mg once daily and increasing to 200 mg after 1–2 weeks if tolerated limits stimulant side effects, which appeared at roughly 225–450 mg single doses.
- Dose ceiling within tested range: Staying at or below 300 mg/day, the highest dose used for eight weeks, avoids the untested range where blood-pressure rises and side effects appeared.
- Morning dosing: Taking theacrine early in the day and keeping doses below 400 mg reduces sleep disruption; 400 mg worsened sleep when taken eight hours before bed and slowed perceived sleep onset even at 12 hours.
- Caffeine budgeting: Limiting added caffeine to 150 mg or less on theacrine days offsets caffeine’s boost to theacrine blood levels and reduces additive blood-pressure and anxiety effects.
- Home blood-pressure checks: Seated readings 1–3 hours after a dose on 3–5 days in weeks 1–2 detect individual blood-pressure rises; a sustained systolic increase of 10 mmHg or more is a common threshold for lowering the dose.
- Liver enzyme screening: Liver enzymes at baseline and 8–12 weeks guard against the uncertain human relevance of rat liver toxicity, especially alongside other liver-stressing supplements or alcohol.
- Third-party tested products: Independently tested products reduce the risk of undeclared stimulants or inaccurate doses in multi-ingredient formulas.
- Pre-test washout: Stopping theacrine at least 5 days before a cardiac stress test prevents interference with adenosine-based test drugs.
Therapeutic Protocol
- Standard dose: Practitioner and product protocols typically use 50–200 mg once daily; trials used 100–400 mg single doses and 200–300 mg daily for up to eight weeks (Taylor et al., 2016).
- Stand-alone approach: Promoted by the TeaCrine marketer Compound Solutions as a caffeine alternative, theacrine alone (100–200 mg) is used by caffeine-sensitive people for steadier energy; trials show inconsistent effects.
- Caffeine-paired approach: Tested most by Shawn Arent’s university research group, roughly equal parts theacrine and caffeine (e.g., 150 mg each) aim for caffeine-level alertness with half the caffeine (Lints et al., 2025).
- Tea-based approach: Traditional kucha tea drinking in southern China supplies theacrine alongside caffeine and other tea compounds, but content per cup is variable and unstandardized.
- Time of day: Morning dosing, 60–90 minutes before demanding work or exercise, is typical; evening doses risk sleep disruption given the long half-life.
- Half-life: Roughly 16–29 hours versus about 5 hours for caffeine, so blood levels build over several days of daily use (He et al., 2017).
- Single versus split dosing: A single morning dose is standard; the long half-life makes split dosing unnecessary and would push exposure closer to bedtime.
- Genetic considerations: No gene variant is known to change theacrine dosing; a 50 mg start is a common conservative approach for people with known caffeine sensitivity, such as slow CYP1A2 or anxiety-prone ADORA2A variants.
- Sex differences: No sex-specific dosing data exist; lighter body weight matters because several trials dosed by weight (3–9 mg/kg), so smaller adults reach higher relative doses.
- Age: Adults over 60 are essentially unstudied; lower starting doses (50 mg) and strict morning timing reflect slower clearance and more fragile sleep in this group.
- Baseline biomarkers: Resting blood pressure, sleep efficiency, and liver enzymes at baseline frame dose choice; elevated blood pressure or poor sleep favors the low end.
- Pre-existing conditions: Hypertension (high blood pressure), anxiety, insomnia, and liver disease carry the greatest uncertainty; no protocol has been studied in these groups.
Discontinuation & Cycling
- Duration: Theacrine is used as-needed or daily for weeks; the longest human data cover eight weeks, so lifelong use is unstudied.
- Withdrawal: No withdrawal symptoms have been reported after stopping, unlike caffeine’s headaches and fatigue, but no trial has formally assessed withdrawal.
- Tapering: No taper protocol is established; the long half-life makes levels fall gradually over several days. When paired with caffeine, tapering the caffeine over 1–2 weeks avoids caffeine-withdrawal headaches.
- Cycling: The eight-week trial found no tolerance (Taylor et al., 2016), so cycling is not required to maintain effect; some users take 5-days-on/2-days-off breaks mainly to limit cumulative exposure, given sparse long-term safety data.
Sourcing and Quality
- Synthetic branded form: TeaCrine is a synthetic, nature-identical theacrine from Compound Solutions, licensed into many products; it was the form used in most human trials.
- Plant sources: Kucha leaves contain theacrine at a few percent of dry weight alongside caffeine; tea brews deliver unstandardized amounts.
- Third-party testing: Batch certificates of analysis and certifications such as NSF Certified for Sport or Informed Sport verify identity, dose, and absence of undeclared stimulants.
- Label transparency: Proprietary blends often hide theacrine and caffeine amounts; single-ingredient products or fully disclosed labels allow accurate dosing.
- Reputable suppliers: Single-ingredient theacrine capsules from retailers that publish batch test results (e.g., Nootropics Depot) offer dose certainty; multi-ingredient pre-workout products are harder to evaluate.
- Manufacturing standards: Products made under current Good Manufacturing Practice rules in facilities audited by independent certifiers carry lower risk of contamination and dose errors.
Practical Considerations
- Time to effect: Subjective energy effects, when present, appeared within 1–3 hours of a dose; the next-morning attention effect followed evening doses. No data show cumulative benefits beyond acute effects.
- Common pitfalls: Taking theacrine late in the day, stacking it with several caffeine sources, expecting exercise-performance gains, and relying on proprietary blends with undisclosed doses.
- Regulatory status: In the US, theacrine is sold as a dietary supplement ingredient, not a drug approved by the Food and Drug Administration. It is not named on the World Anti-Doping Agency Prohibited List; availability elsewhere varies.
- Cost and payers: Typically under US$1 per daily dose. No insurer or national health system pays for theacrine or caffeine, so payer incentives do not shape this evidence; commercial incentives rest with ingredient marketers.
- Evidence funding: Most favorable human trials were funded by, or used products from, Compound Solutions, which markets TeaCrine; independently funded trials were mostly neutral.
Interaction with Foundational Habits
- Sleep: Direct, potentially blunting. Adenosine blockade plus a roughly day-long half-life reduced sleep efficiency at 400 mg taken within eight hours of bed, while 100 mg showed no effect (Gardiner et al., 2024). Morning dosing and wearable sleep tracking address this.
- Nutrition: Indirect. No nutrient depletion is known, and food effects on absorption are unstudied. Kucha tea adds catechins (tea antioxidants) and caffeine; counting caffeine from coffee, tea, chocolate, and energy drinks matters because caffeine raises theacrine exposure.
- Exercise: None to minimal. Theacrine alone did not improve strength, sprint, or endurance performance in trials (Vieira-Cavalcante et al., 2025; Cesareo et al., 2019; Jovanov et al., 2025; Cerqueira et al., 2022); paired with caffeine 60–90 minutes before exercise, it may sharpen reaction time under fatigue. No blunting of training adaptations is reported.
- Stress management: Indirect, potentially potentiating the stress response. High doses raised salivary cortisol (Stoke et al., 2026), and some users report anxiety; limiting doses to 200 mg or less and pairing with calming practices such as breathwork are common, though untested, strategies.
Monitoring Protocol & Defining Success
Baseline testing: Before starting, a baseline panel establishes reference values: seated home blood pressure averaged over three mornings, resting heart rate, liver enzymes, and kidney function, plus one to two weeks of sleep data from a wearable device or sleep diary.
Ongoing monitoring: Blood pressure and resting heart rate are checked 1–3 hours after dosing on 3–5 days during weeks 1–2, then weekly for the first 3 months. Liver enzymes and kidney function are repeated at 8–12 weeks, then every 6–12 months with continued daily use. Sleep metrics are reviewed at 2 weeks and after any dose increase, using the same wearable device or sleep diary as at baseline.
Defining success: Success means a noticeable improvement in the individual’s goal, such as steadier energy, better focus, or reduced caffeine intake, without a sustained systolic rise of 10 mmHg or more, worse sleep efficiency, or rising liver enzymes.
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| Blood pressure (seated, home) | 110–120 / 70–80 mmHg | Detects stimulant-related rise | Conventional threshold for high blood pressure is 130/80 mmHg; measure 1–3 h after dosing, after 5 minutes of seated rest |
| Resting heart rate | 50–70 bpm | Detects stimulant effect | bpm = beats per minute; conventional range 60–100 bpm; measure on waking, before caffeine |
| ALT | 10–25 U/L | Liver-cell injury screen | ALT = alanine aminotransferase, an enzyme released by damaged liver cells; conventional upper limit about 40–55 U/L; no fasting needed; pair with AST |
| AST | 10–25 U/L | Liver and muscle injury screen | AST = aspartate aminotransferase, a liver and muscle enzyme; conventional upper limit about 40 U/L; avoid hard exercise 48 h before testing |
| Creatinine / eGFR | eGFR ≥90 mL/min/1.73 m² | Kidney function reference | eGFR = estimated glomerular filtration rate, a kidney-filtering estimate; conventional normal ≥60; theacrine’s elimination route is uncharacterized |
| Sleep efficiency (wearable) | No established target for theacrine; track change from own baseline (typically ≥85%) | Detects sleep disruption | Compare 2-week averages before and after starting; pair with night-time wake minutes |
Qualitative markers:
- Daytime energy and absence of an afternoon slump
- Focus and sustained attention during long tasks
- Ease of falling asleep and number of night-time awakenings
- Jitteriness, anxiety, palpitations, or headache
- Daily caffeine intake needed to feel alert
Emerging Research
- Ongoing trials: A ClinicalTrials.gov search on 26 September 2026 found no recruiting or active theacrine trials; all six registered studies are completed, so near-term evidence will come from pending publications.
- Unpublished fatigue trial: A 79-participant placebo-controlled trial comparing a theacrine formulation, an Alpinia galanga formulation, and caffeine on fatigue (primary endpoint: fatigue rating scale) finished in 2022 without posted results (NCT05170113); publication could strengthen or weaken the energy claim.
- High-dose safety: A completed 19-participant trial of 3–9 mg/kg (NCT07376564), published as Stoke et al., 2026, found higher cortisol without energy or cognitive benefit, weakening the case for higher doses.
- Caffeine-sparing cognition: A 23-participant tactical-personnel trial (NCT05715073) reported caffeine–theacrine benefits beyond caffeine alone (Lints et al., 2025); independent replication would strengthen this signal.
- Healthy-aging claims: A 12-participant, seven-day study of the theacrine blend NAD3 in adults aged 40–70, run with its marketer Compound Solutions as collaborator (NCT06219161) found changes only in circulating stem-cell counts (Hellenbrand et al., 2024); trials with functional aging outcomes would test the longevity claim.
- Elite-athlete performance: An independent canoe-sprint trial found no benefit from theacrine alone but some from the caffeine combination (Jovanov et al., 2025), weakening stand-alone ergogenic (performance-enhancing) claims.
- Sleep with repeated dosing: Building on Gardiner et al., 2024, trials of daily dosing in older adults could show whether accumulation worsens sleep, which would weaken the case for regular use.
- Liver translation: Rodent protection against fatty liver (Wang et al., 2018) contrasts with rat liver toxicity at very high doses (Clewell et al., 2016); human liver-fat studies would show which direction applies.
Conclusion
Theacrine is a caffeine relative from a Chinese wild tea, sold as a supplement for steady energy and focus. For health-focused adults who value alertness but dislike caffeine’s effects on sleep, blood pressure, or nerves, it offers an appealing idea that human evidence only partly supports.
Taken alone, theacrine’s effects on energy and thinking are small and inconsistent, and it does not appear to improve strength or endurance. The clearest human signal comes from pairing it with a smaller amount of caffeine, which in several trials produced alertness and reaction speed similar to, or slightly better than, a larger caffeine dose. The claim that it keeps working with daily use, unlike caffeine, rests on one short study.
Its promotion for healthy aging, through effects on cell energy and on liver, brain, and inflammation pathways, comes from animal and cell research and has not been tested against aging outcomes in people.
Safety over about two months at moderate doses looks reassuring in young adults, but larger single doses have produced caffeine-like side effects, possible blood pressure rises, and poorer sleep, and very high doses harmed the liver and testes in rats. Older adults and use beyond two months remain essentially unstudied.
The evidence base is small, and most of the favorable trials were funded by, or used products from, the company that markets the branded ingredient, while independently funded trials were largely neutral.